The ASPA gene helps the brain recycle a substance called N-acetylaspartate, which supports normal brain development and the fatty covering around nerves that helps signals travel. If both copies of this gene do not work properly, that substance can build up and disrupt brain function, causing Canavan disease. Babies and children with this condition may have low muscle tone, feeding difficulties, delayed development, and problems with movement. Genetic findings in the ASPA gene are mainly used to diagnose or clarify this inherited condition.
What is a gene?
Genes are sections of DNA that give your cells instructions for making molecules or managing activities in the body. Some genes provide the directions for producing proteins, which are the parts of cells that do much of the work. Others are mainly involved in controlling when certain processes happen, where they happen, and how active they are. Taken together, genes affect how the body grows and works, and they can influence how you respond to food, stress, or medicines. More detailed information on this topic is available in the LearnHub.
Overview
ASPAGene function
What if the gene works
The ASPA gene helps make an enzyme that breaks down N-acetylaspartate, a natural brain chemical. This helps support myelin, the fatty coating that insulates nerves.
Risk
What if the gene does not work
Pathogenic variants in the ASPA gene cause Canavan disease, which affects brain white matter. Babies often have low muscle tone, delayed development, and feeding problems. Milder or more severe variants can influence when signs begin and how noticeable they are.
Treatment
What does that mean for your treatment
No ASPA-specific treatment or drug selection approach is currently established; care remains supportive and guided by symptoms rather than the exact ASPA variant. The ASPA gene is being studied as a target for gene therapy and other experimental approaches in Canavan disease.
Conditions associated with ASPA
Gene function
What if the gene works
In the brain, your cells use the ASPA gene to process a natural substance called N-acetylaspartate, or NAA. This keeps brain chemistry more balanced and releases acetate, a small building block cells can reuse. Those everyday steps support white matter, the brain’s wiring, and normal cell activity.
The ASPA gene helps break down N-acetylaspartate in the brain. This turns NAA into aspartate and acetate so these parts can be handled and reused by cells.
One product made by ASPA activity is acetate, a small molecule cells can use as a building block. In the brain, that acetate supports making fats that are part of myelin, the coating around nerve fibers.
By helping manage NAA and provide acetate, the ASPA gene supports normal white matter maintenance. This helps nerve cells and nearby support cells work together in a steady, routine way.
What is a variant?
A genetic variant is a minor difference in the DNA sequence within a gene. These differences are common and are part of normal human diversity, including variation in appearance, metabolism, and the way the body responds to environmental influences. Many do not cause any noticeable effect and simply represent natural genetic variation. Sometimes, though, a variant changes how a gene functions more substantially and can contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Understanding how variants influence the ASPA gene's function starts with the fact that many changes reduce or shut down the enzyme by altering its shape, stability, or active site. This can lead to buildup of N-acetylaspartate, a brain chemical, inside cells. Milder variants may leave some enzyme activity, while more severe variants often leave little or none and are linked to earlier onset or more marked features of Canavan disease.
How variants are linked to conditions
Pathogenic variants in the ASPA gene cause Canavan disease, a rare inherited condition that affects brain development, movement, and muscle tone. Finding two disease-causing ASPA gene variants can confirm the diagnosis. ASPA gene variants and Canavan disease are seen in many populations worldwide, with some variants reported more often in people of Ashkenazi Jewish ancestry.
A variant is not necessarily a diagnosis
Variants in genes are a routine feature of human biology and are widely seen across the general population. Most do not directly affect health and simply contribute to normal human variation. For many genes, having a variant associated with a condition points to a potential link rather than a certain diagnosis, particularly when several genes and environmental influences play a role. In other situations, though, one well-characterized variant in a particular gene is enough to establish the diagnosis.
Are there things that can increase or change my risk?
For ASPA, risk is mostly shaped by inheritance rather than lifestyle. Having a family history of an ASPA-related condition, having a partner who also carries an ASPA variant, or having Ashkenazi Jewish ancestry can raise the chance of having a child with this condition.
Inheritance of ASPA variants
Variants in the ASPA gene are inherited in an autosomal recessive pattern. This means a child usually develops ASPA-related Canavan disease only after inheriting one nonworking copy from each parent. Parents who each carry one ASPA gene variant are typically unaffected, but with each pregnancy there is a 25% chance the child will inherit both variants, a 50% chance the child will be a carrier, and a 25% chance the child will inherit neither variant. In plain terms, the ASPA gene inheritance pattern usually involves both parents passing on a variant.
What does my ASPA result mean for my family?
ASPA results are most often discussed in relation to Canavan disease, which is usually passed down in a recessive way. For family members, this mainly means brothers, sisters, and other close relatives could be carriers, even if they are healthy, and in some families another child could also be affected. The meaning for relatives depends on whether your result shows one changed copy or two changed copies of the ASPA gene.
Genetic information
Genetic testing
How you find out about variants
To find ASPA variants, clinicians use ASPA genetic testing, which reads the ASPA gene from a blood sample or cheek swab. This can confirm whether a person carries a disease causing variant or has two ASPA variants linked to Canavan disease. Results are interpreted with symptoms and family history.
When should I consider getting a genetic test?
Consider ASPA testing if a baby or child has signs that fit Canavan disease, such as poor head control, low muscle tone, developmental delay, or an unusually large head. Testing can also be helpful if Canavan disease runs in your family or if you and your partner want carrier testing, especially with Ashkenazi Jewish ancestry.
A genetic result is only one part of your health story
A genetic result can be very informative, but what it can tell you varies by the condition and the type of variant. Over time, how the body works is also shaped by factors such as lifestyle, environment, age, and medical history. For some conditions, especially ones influenced by many genes, genetic information offers context rather than certainty and is most useful when viewed alongside the rest of care. In other situations, a genetic result can give a clear answer. In areas like medication response, genetic results may also help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Small differences in DNA can change how the body breaks down a drug, moves it through the body, or responds to it at its target. This helps explain why the same treatment may work well for one person, work less well for another, or cause more side effects in someone who is more sensitive to it.
What is Pharmacogenetics?
Pharmacogenetics is the area of study that examines how genetic differences can affect the way a person responds to medication. It looks at connections between genes and drugs to help explain why the same treatment can work differently from one person to another. For many medicines, genes can influence how strongly a drug works or how the body handles it. This information can support treatment decisions that are more informed and more individualized. More on this topic is available in the LearnHub.
Drugs influenced by the ASPA gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medicine choices, so any concerns about medications, side effects, or your overall health are best discussed with your doctor.
History
Canavan disease, the condition linked to changes in the ASPA gene, was first described in 1931 by the neuropathologist Myrtelle Canavan after she recognized a distinct pattern in affected infants’ brains. For decades, doctors could identify the condition only by its clinical features and later by brain imaging and lab findings. In the 1990s, researchers connected the condition to the ASPA gene, which made carrier screening and genetic testing much more precise, especially in Ashkenazi Jewish communities where several founder variants were recognized. From these first observations, research expanded steadily. The gene also became part of an important debate about consent, tissue use, and gene patenting, helping shape later conversations about ethics in genetic research.